+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07356882

Using ctDNA to Monitor Treatment and Predict Outcomes in Children and Young Adults with Classical Hodgkin Lymphoma

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-21

400

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Classical Hodgkin lymphoma cHL is a common cancer in children and adolescents, representing the leading cause of cancer during adolescence. Although current treatments combining chemotherapy and radiation have greatly improved outcomes, about 10-15% of patients still experience relapse or resistant disease. This research explores the use of circulating tumor DNA ctDNA as a biomarker to improve early risk detection, treatment monitoring, and relapse identification in pediatric cHL, aiming to refine treatment strategies and reduce long-term side effects. The study involves analyzing ctDNA at four different timepoints during standard treatment to assess tumor mutations and disease progression without invasive biopsies. This approach will be compared with current imaging methods like PETCT scans to evaluate its accuracy and usefulness. The project combines efforts from France and Germany to harmonize ctDNA testing methods and integrate molecular data with clinical outcomes, ultimately guiding personalized treatment plans. Participants will have blood samples collected at key stages during their therapy to measure ctDNA levels, alongside routine imaging and clinical assessments. Researchers will track relapse-free survival over 2 and 5 years based on ctDNA findings and examine ctDNAs diagnostic performance after chemotherapy cycles and at treatment completion. Long-term monitoring up to 5 years will study molecular changes at relapse, providing insight into disease behavior and treatment response.

CONDITIONS

Brief Title

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

Research Team

M

Mathieu SIMONIN, Medical Doctor

F

Fabrice JARDIN, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here